JETIR.ORG

ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue

JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR) An International Scholarly Open Access, Peer-reviewed, Refereed Journal

IMPACT OF MULTICOMPONENT PROGRAM TO PREVENT DELIRIUM AMONG CRITICALLY ILL PATIENTS ADMITTED IN ICUS.

¹DikshaThakur, ²Dr. Jyoti Sarin, ³Pooja Jaswal, ⁴Dr. B.K. Agrawal

¹ M.Sc. Nursing Tutor, ²RN. RM. MN. Ph.D. (Nursing)Dean- Principal, ³RN. RM. M.Sc. (Nursing) Assistant Professor. ⁴MD, FICP, FIACM. Principal

¹Department of Medical Surgical Nursing

¹ M.M. College of Nursing, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India

ABSTRACT

Objectives: Evaluating the effectiveness of Multicomponent Programme on prevention of delirium among critically ill patients.

Methods: A quantitative approach with non-equivalent control group pre test- post test design. Setting of the study was Hospitals of Mullana, Ambala, and Haryana. A total of 90 critically ill patients admitted in intensive care unit were recruited by purposive sampling and allocated into experimental group (n=45), comparison group (n=45). The tool used for the study consisted of selected variables, clinical variable, Memorial Delirium Assessment Scale. In comparison group pre test was conducted. 2nd day to 4th day routine care was provided. Daily assessment of delirium scores were done till 6th day. Post test was conducted at 5th day. In experimental group on day one pre test was conducted, 2nd day to 4th day Multicomponent program was administered. Daily assessment of delirium scores were done till 6th day. Post test was conducted at 5th day.

Results: Significant difference was noticed in delirium scores between experimental, and comparison group (p=0.00). **Conclusion:** Findings concluded that the Multicomponent Program was effective in

prevention of delirium, although the patients received intervention were having decreased scores than comparison group.

Keywords: Multicomponent program, delirium prevention, critically ill patients.

Introduction

Delirium is defined as a disturbance in attention, consciousness and cognition with reduced capacity to direct, focus, sustains and change attention, and reduced orientation to the environment. Critically ill patients in the intensive care unit (ICU) often develop ICU delirium. It is associated with increased mortality, extended duration of mechanical ventilation, extended hospital and ICU stay and long-term cognitive impairment. Typically, delirium causes fluctuating disturbance in attention, cognition, and consciousness which significantly complicates the delivery of care and reduce the prognosis.¹

Estimated that 35.6 million people worldwide affected due to delirium. Incidence and prevalence rate of delirium were 24.4% and 53.6% in INDIA. Delirium in the intensive care unit is a thoughtful problem that has recently attracted more attention.²

Delirium patients are at risk of developing various complications, including infections like pneumonia and urinary tract infections, pressure ulcers, venous thromboembolism, poor recovery from surgery. These patients are at a greater risk of extended periods of mechanical ventilation and associated complications, such as aspiration, nosocomial pneumonia, and decline in health, increased risk of death.³

Delirium prevention approaches to improve overall excellence of hospital care. This program comprises the following: maintaining orientation to surroundings and sleep; encouraging mobility within the limits of physical condition; and providing visual and hearing adaptations for patients with sensory losses, cognitive stimulation.⁴

A study was conducted to assess Multicomponent intervention may decrease delirium incidence, and/or its duration and severity, in inpatients with progressive cancer. Results shows the primary outcome is adherence to the intervention through the first seven days of admission, measured for 40 consecutively admitted eligible patients. Secondary outcomes relay to fidelity and feasibility, suitability and sustainability of the study intervention, processes and measures in this patient population, using quantitative and qualitative measures. Delirium incidence and severity will be measured to inform power calculations for a upcoming phase III trial. This sample size depended on that anticipated for the future stage III bunch RCT of the intercession with: two equal arms, 50% delirium rate in the control, 30% delirium in intervention group, cluster size of 30 and intraclass correlations of 0.05, type I error rate of 5%, 80% power to reject the null hypothesis and 30% attrition.⁵

Limited studies have been conducted on efficacy of Multicomponent program on prevention of delirium. Screening and assessments as a routine measure should be done, for patients. To improve the care outcomes of the patients and prolonged hospital stay of patients. Therefore it is necessary to assess the occurrence of delirium in ICU patient, administer delirium prevention and management program. Thus, this study is aimed at to evaluate the effectiveness of delirium prevention & management programme on occurrence of delirium among patients admitted in ICU of selected hospital Mullana, Ambala, Haryana.

The objective of the study is to evaluate the effectiveness of Multicomponent Programme on prevention of delirium among critically ill patients.

METHODS

OBJECTIVE: To assess and compare the scores of delirium among critically ill patients admitted in intensive care units before and after administration of Multicomponent program in experimental and comparison group. The study used quantitative approach and non-equivalent control group pre test- post test design. The study was conducted at Hospitals of Ambala, Haryana.

Population and Sample

A total of 90 critically ill patients admitted in intensive care unit were recruited by purposive sampling and allocated into experimental group (n=45), comparison group (n=45). The tool used for the study consisted of selected variables regarding study participants characteristics, clinical variables, Memorial Delirium Assessment Scale to assess the delirium scores. Reliability of the tools was established by chronbach alpha for Memorial Delirium Assessment Scale (0.99)

Data and Sources of Data

The data collection was done during the period of November to December 2019. In comparison group pre assessment of selected variables, clinical variables and delirium scores were done. Daily assessment of delirium scores were done till 6th day. 2nd day to 4th day routine care was provided. Post test was conducted at 5th day. In experimental group on day one pre assessment of selected variables, clinical variables and delirium scores were done. Daily assessment of delirium scores were done till 6th day. 2nd day to 4th day Multicomponent program was administered. Multicomponent program consist of (orientation, sensory stimulation by music therapy, mobilization, cognitive stimulus, sleep promotion). Post test was conducted at 5th day. Attrission of 14 patients in experimental group and 12 patients in comparison group due early discharge. Data analysis was done using both descriptive and inferential statistics i.e. "t" test, Repeated Measures ANOVA

Theoretical Framework

The conceptual framework in this study is based on Betty Neuman Model, aimed at to assess the effectiveness of Multicomponent program on prevention of delirium, among

critically ill patients admitted inICUs (Deemed to be University) Mullana, Ambala.

Betty Neuman's System Model provides a comprehensive, holistic and system- based approach to nursing that contains an element of flexibility. The theory focuses on the response of the patient system to actual or potential environment stressors and the use of primary, secondary, and tertiary nursing prevention intervention for retention, attainment and maintenance of patient system wellness.

DATA ANALYSIS

According to the objectives and hypotheses of the study and opinion of experts was planned to organize, tabulate and interpret the data by using both descriptive and inferential statistics i.e. Mean, Median and standard deviation, and "t" test, Repeated Measures ANOVA.




Fig.1: Consort diagram for sample selection

RESULTS AND DISCUSSION

The Kolmogorov- Smirnov test was applied to check the normality of data distribution between the samples regarding prevention of delirium among critically ill patients and scores of delirium in pre test (p=) was normally distributed as calculated K-S value was not significant at 0.05 level of significance. Hence parametric test was applied for both comparison and experimental group.

Comparison of experimental and comparison group in terms of socio demographic and clinical variables

TABLE 1. Comparison of delirium patients in terms of Socio Demographic

				N=	:90
Socio demographic variables	Experiment al group n=45 f (%)	Comparis on group n= 45 f(%)	χ2	D f	p valu e
1.Age	2 (/ 0)				
1.1 18-32	9(20.0)	9(19.6)			
1.2 33-47	8(17.8)	13(28.3)	30		
1.3 48-62	9(20.0)	7(15.2)	1.7	4	0.78
1.4 62- 77	18(40.0)	15(32.6)	1		NS
1.5 > 77	1(2.2)	1(2.2)			
2.Gender	A A	4			
2.1 Male	16(35.6)	21(46.7)	1.1	1	0.28
2.2 Female	29(64.4)	24(53.3)	4		NS
3.Marital status					
3.1Married	28(62.2)	35(77.8)	/		
3.2Unmarried	6(13.3)	3(6.7)	2.7	3	0.42
3.3Divoeced/separa	1(2.2)	1(2.2)	7		NS
ted	10(22.2)	6(13.3)			
3.4Widow					
4.Educational					
status	16(35.6)	12(26.7)			
4.1No formal	10(22.2)	17(37.8)			
education	16(35.6)	11(24.4)	3.8	4	0.42
4.2 Primary 4.3 Up to 10 th	2(4.4)	3(6.7)	4		NS
standard 4.4 Up to higher secondary	1(2.2)	2(4.4)			
4.5 Graduate and above					
5.Occupation					
5.1 Unemployed	8(17.8)	11(24.4)			
5.2 Home maker	26(57.8)	23(51.1)	5.5	4	0.23
5.3 Self employed	7(15.6)	3(6.7)	3		NS
5.4 Private job	3(6.7)	8(17.8)			
5.5 Government job	1(2.2)	0			

6.Alcohol abuse					
6.1 Yes	8(17.8)	15(33.3)	2.8	1	0.91
6.2 No	37(82.2)	30(66.7)	6		NS

 χ 2 at (1)=3.84,(2)=5.991, (3)=7.815,(4)=9.488, (6)=12.592

NS – Non significant (p>0.05)

*-Significant (p≤0.05)

TABLE 2. Comparison of delirium patients in terms of clinical variables

N=90

			lhe.	and a	
Clinical Variable	Experime	Compar	χ2	Df	p value
	ntal	ison			
	group	group			
	n=45	n= 45			
1.1416	f(%)	f(%)	Aller Aller Water		
1. Length of		4 1	Mar.		
stay in ICU 1.1 1 to 3 days	44(97.8)	43(95.6)	-317		
•			0.34	1	0.57^{NS}
1.2 4 to 6 days	1(2.2)	2(4.4)	0.34	1	0.57
1.3 7 to 10 days 1.4 11 to 14	A NE				
				4 6	
days					
2. Diagnosis on					
admission			, 6M		
2.1 GU Disease	1(2.2)	0	/ A)-		
2.2GI Diseases	4(8.9)	4(8.9)			
2.3 CV disease	4(8.9)	0	7.86	<i>A</i> 7	$0.34^{ m NS}$
2.4 Respiratory	0	2(4.4)			0.0
2.5 CNS	2(4.4)	2(4.4)			
2.6 Endocrine	2(4.4)	1(2.2)			
2.7 Dengue	7(15.6)	6(13.3)			
Fever	25(55.6)	30(66.7)			
2.8Multiple	, ,	,			
disease					
Q3. Co morbid					
illness					
3.1 Yes	12(26.7)	13(28.9)	0.05	1	1.00^{NS}
3.2 No	33(73.3)	32(71.1)			
4. History of					
renal disease					
4.1 Yes	6((13.3)	18(40.0)	8.18	1	0.00^{*}
4.1 Tes 4.2 No	39(86.7)	27(60.0)	0.10	1	3.00
5.History of	` '	` '			
liver disease					
5.1 Yes	7(15.6)	8(17.8)	0.08	1	0.77^{NS}

5.2 No	38(84.4)	37(82.7)			
6. Hearing					
status	45(100)	45(100)	-	-	-
6.1 Intact	0	0			
6.2 Impaired					
7.Visual status					
	17(27.9)	22(49.0)	1.31	1	$0.28^{ m NS}$
7.1 intact	17(37.8)	22(48.9)	1.31	1	0.28
7.2 impaired	28(62.2)	23(51.1)			
8.Ambulatory					
status	7(15.6)	10(22.2)			
8.1 Dependent	37(82.2)	34(75.6)			
8.2 Partially	1(2.2)	1(2.2)	0.65	2	0.72^{NS}
dependent					
8.3. Ambulatory					
9. Physical					
restrain	4(8.9)	3(6.7)	0.15	1	0.69^{NS}
9.1 Yes	41(91.1)	42(93.3)			
9.2 No					
			ALL		
10. Sleeping			6		
pattern	17(37.8)	15(33.3)	AA.		
10.1 No sleep	22(48.9)	24(53.3)	0.04	2	0.97^{NS}
$10.2 \ 1 - 3 \ \text{hours}$	6(13.3)	6(13.3)	0.01	_	0.57
$10.3 \ 4 - 6 \ \text{hours}$	0(13.3)	0(13.3)			
10.47 - 8 hours			The second		
10.4 - 8 hours 10.5 > 8 hours			Salar S	(4 B)	
Q11. Pain				V . W	
	12(26.7)	11(24.4)			
11.1 0 – No pain	12(26.7)	11(24.4)	0.24		$0.84^{ m NS}$
11.2 1 – 3 Mild	27(60.0)	26(57.8)	0.34	2	0.84
11.34 – 6	6(13.3)	8(17.8)		er M	
Moderate					
11.4 7 - 10	The sa				
Severe					
12.Use delirium					
inducing of					
Medications					NIC
12.1 No	23(51.1)	21(46.7)	6.80	4	0.14^{NS}
12.2 Analgesics	15(33.3)	20(44.7)			
12.3Sedative	1(2.2)	1(2.2)			
12.4Anticholine	5(11.1)				
rgic drugs	1(2.2)	3(6.7)			
12.5		0			
Anticonvulsant					
Q13. Blood					
pressure					
13.1<80/<60	24(53.3)	25(55.5)			
13.2 80-120/60-	15(33.3)	15(33.3)	0.22	3	0.68^{NS}
79	3(6.7)	2(4.4)			
	3(6.7)	3(6.7)			
13.3 120-	- ()	- ()			

139/80-89

159/90-99	13.4 140-					
Q14.Blood Values Hb 14.1<0 23(51.1) 21(46.7) 1.11 3 0.77 ^{NS} 14.2 10-13 18(40) 17(37.8) 14.3 13-15 3(6.7) 6(13.3) 14.4>15 1 (2.2) 12.2) 15.3GOT 15.1 decreased 0 0 15.2 normal 12(26.7) 15(33.3) 4.76 1 0.49* 15.3 increased 33(73.3) 30(66.7) 1 0.49* 16.8 GPT 16.1 decreased 0 0 0 0.45 NS 16.3 increased 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 NS 17.3 increased 36(80.0) 33(73.3) 33(73.3) 17.8 Ilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 NS 17.3 increased 20(44.4) 14(31.1) 18.1 decreased 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 NS 18.3 increased 28(62.2) 34(75.6) 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 NS 19.3 increased 20(44.4) 24(53.3) 20. ABG 20(44.4) 24(53.3) 20.1 y	159/90-99					
Values Hb 14.1 23(51.1) 21(46.7) 1.11 3 0.77 ^{NS} 14.2 10-13 18(40) 17(37.8) 14.3 13-15 3(6.7) 6(13.3) 14.4>15 1(2.2) 1(2.2) 15.3 (6.7) 1(3.3) 1.11 3 0.77 ^{NS} 15.4 15 1(2.2) 1(2.2) 1.11 3 0.77 ^{NS} 1.11 3 0.77 ^{NS} 15.3 15 3(6.7) 6(13.3) 1.12 1.1	13.5 > 160/> 100					
Values Hb 14.1<0 23(51.1) 21(46.7) 1.11 3 0.77^{NS} 14.2 10-13 18(40) 17(37.8) 14.3 13-15 3(6.7) 6(13.3) 14.4>15 1(2.2) 12.2) 12.2) 15.3 16.3 16.5 17.3 16.5 16.5 17.3 16.5 17.3 16.5 17.3 16.5<						
14.1<10	_					
14.2 10-13		02(51.1)	21(46.7)	1 11	2	0.77NS
14.3 13-15		, ,		1.11	3	0.77
14.4>15		` '	` /			
15.SGOT 15.1 decreased 0 0 0 15.2 normal 12(26.7) 15(33.3) 4.76 1 0.49* 15.3 increased 33(73.3) 30(66.7) 16. SGPT 16.1 decreased 0 0 0 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 ^{NS} 16.3 increased 36(80.0) 33(73.3) 17. Bilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6)		, ,	* *			
15.1 decreased 0 0 0 15.2 normal 12(26.7) 15(33.3) 4.76 1 0.49* 15.3 increased 33(73.3) 30(66.7) 16. SGPT 16.1 decreased 0 0 0 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 ^{NS} 16.3 increased 36(80.0) 33(73.3) 17. Bilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6)		1(2.2)	1(2.2)			
15.2 normal 12(26.7) 15(33.3) 4.76 1 0.49* 15.3 increased 33(73.3) 30(66.7) 16. SGPT 16.1 decreased 0 0 0 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 ^{NS} 16.3 increased 36(80.0) 33(73.3) 17. Bilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no		0	0			
15.3 increased 16. SGPT 16.1 decreased 16.2 normal 16.3 increased 36(80.0) 17. Bilirubin 17.1 decreased 17.2 normal 18. Urea 18.1 decreased 18.2 normal 16(35.6) 18.3 increased 18.3 increased 18.4 decreased 19.1 decreased 19.1 decreased 19.2 normal 19.3 increased 20(44.4) 20.12 ^{NS} 20. ABG analysis 18(40.0) 20(44.4) 20(18.4) 2				476	1	0.40*
16. SGPT 16.1 decreased 0 0 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 NS 16.3 increased 36(80.0) 33(73.3) 33(73.2) 33(6.6) 33(, ,		4.76	1	0.49
16.1 decreased 0 0 16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 ^{NS} 16.3 increased 36(80.0) 33(73.3) 1 0.45 ^{NS} 17. Bilirubin 17.1 decreased 0 1(2.2) 0.28 ^{NS} 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 1 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 2 0.11 ^{NS} 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 25(55.6) 20.2 no		33(73.3)	30(66.7)			
16.2 normal 9(20.0) 12(26.7) 0.55 1 0.45 ^{NS} 16.3 increased 36(80.0) 33(73.3) 1 0.45 ^{NS} 17. Bilirubin 17.1 decreased 0 1(2.2) 0.28 ^{NS} 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 1 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6)			0			
16.3 increased 36(80.0) 33(73.3) 17. Bilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) <t< td=""><td></td><td></td><td></td><td>0.55</td><td></td><td>0. 45NS</td></t<>				0.55		0. 45NS
17. Bilirubin 17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 3(6.6) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) <td></td> <td></td> <td></td> <td>0.55</td> <td>1</td> <td>0.45</td>				0.55	1	0.45
17.1 decreased 0 1(2.2) 17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6)		36(80.0)	33(73.3)			
17.2 normal 25(55.6) 30(66.7) 2.51 2 0.28 ^{NS} 17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no			1(2.2)	THE THE WAY		
17.3 increased 20(44.4) 14(31.1) 18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no			200	0.51		0.20NS
18. Urea 18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6)		1 1	TO THE PERSON AND THE	2.51	2	0.28
18.1 decreased 1(2.2) 3(6.6) 18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6) </td <td></td> <td>20(44.4)</td> <td>14(31.1)</td> <td>A TAKE</td> <td></td> <td></td>		20(44.4)	14(31.1)	A TAKE		
18.2 normal 16(35.6) 8(17.8) 4.24 2 0.12 ^{NS} 18.3 increased 28(62.2) 34(75.6		1(2.2)	2466			
18.3 increased 28(62.2) 34(75.6) 19. Creatinine 19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no				104		0.10NS
19. Creatinine 19.1 decreased 4(8.9) 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 4.36 2 0.11 ^{NS} 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no 0.18 1 0.67 ^{NS}		Wallet A Version		4.24	2	0.12
19.1 decreased 4(8.9) 0 19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no		28(62.2)	34(75.6)			
19.2 normal 21(46.7) 21(46.7) 4.36 2 0.11 ^{NS} 19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no		4(00)				
19.3 increased 20(44.4) 24(53.3) 20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no		700 300		125		0.11NS
20. ABG analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no		4500	All I	4.36	2	0.11
analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no	19.3 increased	20(44.4)	24(53.3)		, N	
analysis 18(40.0) 20(44.4) 0.18 1 0.67 ^{NS} 20.1 yes 27(60.0) 25(55.6) 20.2 no	••• • • • • • • • • • • • • • • • • •		KA 🗸 📑			
20.1 yes 27(60.0) 25(55.6) 20.2 no		10(10.0)	20(44.4)	0.10		0 c7NS
20.2 no	•			0.18	1	0.6/10
THE REAL PROPERTY OF THE PROPE	•	27(60.0)	25(55.6)			
	20.2 no		.2 .4(1) 2	041 (2) 5 001	(2) 7.015 (4)	0.400 (() 12.5

 χ 2 at(1)=3.841,(2)=5.991, (3)=7.815,(4)=9.488, (6)=12.592

NS – Non significant (p>0.05)

*-Significant (p≤0.05)

Evaluation of effectiveness of Multicomponent program on prevention of delirium

Before administration of Multicomponent program

Level of delirium before administration of Multicomponent program. More than half of critically ill patients in experimental (57.8%) and in comparison group (55.6%) were at risk of delirium

TABLE 3. Delirium scores of patients before administration of Multicomponent program.

N=90s

	Experimental	Comparison					p value
MDAS	group (n=45)	group (n=45)	M_D	SEMD	t	df	
	Mean±SD	Mean±SD			value		

t(88) = 1.9873

NS-Non significant(p>0.05)

*Significant(p≤0.05)

After administration of Multicomponent program




Fig.2 Bar diagram showing frequency and percentage of level of delirium after administration of Multicomponent program in experimental group patients admitted in ICU (At 5th day).

TABLE 4. Delirium scores before and after administration of Multicomponent program

N=90

Group	Test	Mean	F value	p value
Experimental	Pre test	11.56		
group	2 nd day	11.20	169.88	0.00*
(n=45)	3 rd day	9.20		
	4 th day	7.02		
Comparison	Pre test	9.60		
group	2 nd day	9.82	0.41	0.63^{NS}
(n=45)	3 rd day	9.67		
	4 th day	9.51		
NS- Non signific	cant (p>0.05)		*Significan	t (p≤0.05)

TABLE 5. Post Hoc showing significant mean difference in RM –ANOVA value of delirium scores before and after administration of Multicomponent program.

N=90

Group	Category	MD	SE	p value
Experimental	Pre test Vs post	3.56	0.159	0.18 ^{NS}
group	test 2 nd day			
(n=90)				
	Pre test Vs post test	2.35	0.23	0.00*
	3 rd day			
	Pre test Vs Post test	4.53	0.30	0.00*
	4 th day			
	Post test 2 nd day	2.00	0.19	0.00*
	VS Post test 3 rd day	V - 3	Ra II	
			3 4. 1	
	Post test3 rd day VS	2.17	0.18	0.00*
	Post test 4 th day		A. I	

NS Non significant (p>0.05)

*Significant (p<0.05)

TABLE 6. Delirium scores after administration of Multicmponent program

N=90

	Experime	Comparis					p
MDAS	ntal group	on group	· ·		t	Df	value
	(45)	(45)	$\mathbf{M}_{\mathbf{D}}$	SE	valv		
	Mean±SD	Mean±S		MD	e		
		D					
Day 5 th							
(n 64)	5.97±2.35	9.91±2.73	3.94	0.63	6.16	62	0.00^{*}
						t (62)= 1.9	990

NS-Non significant (p>0.05)

*Significant (p≤0.05)

TABLE 7. Delirium before and after administration of Multicomponent program in experimental and comparison group at 5^{th} day.

N=65

Group	Test	Mean±SD	M_{D}	SE _{MD}	t	Df	p value
					value		
Experimental group	Pre test	11.64±3.09	5.67	0.35	16.16	30	0.00^{*}
(n=31)	5 th day	5.97±2.35					
Comparison group							
(n=33)	Pre test	9.75±3.58	0.16	0.53	0.28	32	0.78^{NS}
	5 th day	9.91±2.73					
				1 10			

t at 30=1.697,t(32)=1.6939

NS- Non significant (p>0.05)

*significant (p≤0.05)

TABLE 8. Association between pre test scores of delirium and clinical variables of critically ill patients

N=90

			8	TO A						
Clinical Variable	Experim	Mean	df	F/t	p	Compar	Mean	df	F/t	p
	ental 🦷	34	h.		value	ison				value
	group				w _ /	group				
	n=45					n=45	/			
	f(%)	The same of	-	1		f(%)				
1. Length of stay in										
ICU										
1.1 1 to 3 days	44(97.8)	2.29	43	0.49	0.62^{NS}	43(95.6)	2.02	43	0.48	0.96^{NS}
1.2 4 to 6 days	1(2.2)	2.00				2(4.4)	2.00			
2. Diagnosis on										
admission										
2.1 GU Disease	1(2.2)	2.00								
2.2GI Diseases	4(8.9)	2.50	6/38	0.88	0.51^{NS}	4(8.9)	1.75	5/39	0.32	0.89^{NS}
2.3 CV disease	4(8.9)	1.75				, ,				
2.4 Respiratory						2(4.4)	2.00			
2.5 CNS	2(4.4)	2.50				2(4.4)	2.50			
2.6 Endocrine	2(4.4)	2.50				1(2.2)	2.00			
2.7 Dengue Fever	7(15.6)	2.14				6(13.3)	2.00			
2.8Multiple disease	25(55.6)	2.36				30(66.7)	2.02			

Q3. Co morbid illness 3.1 Yes	12(26.7) 33(73.3)	2.16 2.33	43	0.83	0.40 ^{NS}	13(28.9) 32(71.1)	2.07	43	0.35	0.72 ^{NS}
3.2 No 4. History of renal disease 4.1 Yes 4.2 No	6((13.3) 39(86.7)	2.33 2.28	43	0.19	$0.84^{ m NS}$	18(40.0) 27(60.0)	2.00 2.03	43	0.18	0.85^{NS}
5.History of liver disease 5.1 Yes 5.2 No	7(15.6) 38(84.4)	2.28 2.28	43	0.01	0.98 ^{NS}	8(17.8) 37(82.7)	1.87 2.05	43	0.69	0.49 ^{NS}
6. Hearing status 6.1 Intact 6.2 Impaired	45(100)	-	-	_^	-	45(100)	-	-	-	-
7.Visual status7.1 intact7.2 impaired8.Ambulatory	17(37.8) 28(62.2)	2.35 2.25	43	0.56	0.57 ^{NS}	22(48.9) 23(51.1)	1.90 2.13	43	1.13	0.26 ^{NS}
status 8.1 Dependent 8.2 Partially dependent	7(15.6) 37(82.2) 1(2.2)	2.57 2.24 2.00	2/42	1.04	0.36 ^{NS}	10(22.2) 34(75.6) 1(2.2)	2.30 1.97 1.00	2/42	2.34	0.10 ^{NS}
8.3. Ambulatory	//	5			a La NC) Z				*
9. Physical restrain 9.1 Yes 9.2 No	4(8.9) 41(91.1)	2.75 2.24	43	1.67	0.10 ^{NS}	3(6.7) 42(93.3)	3.00 1.95	43	2.88	0.00^{*}
10. Sleeping pattern 10.1 No sleep 10.2 1 – 3 hours 10.3 4 – 6 hours	17(37.8) 22(48.9) 6(13.3)	2.41 2.22 2.16	2/42	0.60	0.48 ^{NS}	15(33.3) 24(53.3) 6(13.3)	2.46 1.75 2.00	2/42	7.00	0.00^{*}
10.4 7 – 8 hours										
Q11. Pain 11.1 0 – No pain 11.2 1 – 3 Mild 11.3 4 – 6 Moderate 11.4 7 – 10 Severe	12(26.7) 27(60.0) 6(13.3)	2.16 2.37 2.16	2/42	0.63	0.53 ^{NS}	11(24.4) 26(57.8) 8(17.8)	2.09 1.88 2.37	2/42	1.85	0.16 ^{NS}
12.Use delirium inducing of Medications 12.1 No 12.2 Analgesics 12.3Sedatives 12.4Anticholinergic	23(51.1) 15(33.3) 1(2.2) 5(11.1)	2.43 2.13 3.00 2.00	4/40	1.38	0.25 ^{NS}	21(46.7) 20(44.7) 1(2.2) 3(6.7)	2.09 1.95 3.00 1.66	3/41	1.21	.316 ^{NS}
drugs	1(2.2)	2.00								

12.5Anticonvulsant Q13. Blood										
pressure 13.1<80/<60	24(53.3)	2.16	3/41	0.93	0.43^{NS}	25(55.5)	2.08	3/41	0.68	0.56^{NS}
13.2 80-120/60-80	15(33.3)	2.40				15(33.3)	1.86			
13.3 120-139/80-89	3(6.7)	2.33				2(4.4)	2.50			
13.4 140-159/90-99	3(6.7)	2.66				3(6.7)	2.00			
Q14.Blood Values										
Hb										
14.1<10	23(51.1)	2.39	2/11		o - MC	21(46.7)	1.95	0.44	4.00	o o Ne
14.2 10-13	18(40)	2.16	3/41	0.55	0.64^{NS}	17(37.8)	2.05	3/41	1.38	0.26^{NS}
14.3 13-15 14.4>15	3(6.7)	2.33				6(13.3)	2.33 1.00			
14.4>13 15.SGOT	1(2.2)	2.00				1(2.2)	1.00			
15.1decreased										
15.2 normal	12(26.7)	2.25	43	0.26	0.79 ^{NS}	15(33.3)	1.93	43	0.63	0.52^{NS}
15.3increased	33(73.3)	2.30				30(66.7)	2.06			
				7						
16. SGPT					100	A P				
16.1decreased		6.5		/	A MC	. Wh.	4			NC
16.2 normal	9(20.0)	2.33	43	0.25	0.80^{NS}	12(26.7)	2.08	43	0.37	0.71^{NS}
16.3increased	36(80.0)	2.27	1			33(73.3)	2.00			
17. Bilirubin 17.1 decreased		A.2				1(2.2)	2.00			
17.1 decreased 17.2 normal	25(55.6)	2.24	43	0.61	0.53 ^{NS}	30(66.7)	1.96	2/42	0.33	0.71^{NS}
17.2 normal	20(44.4)	2.35	73	0.01	0.55	14(31.1)	2.14	2/42	0.55	0.71
1,16 1110104500	= 5()						1			
18. Urea	# .	Ta .								
18.1 decreased	1(2.2)	2.00	2/42	0.53	0.59^{NS}	3(6.6)	2.00	2/42	0.00	0.99^{NS}
18.2 normal	16(35.6)	2.18				8(17.8)	2.00			
18.3 increased	28(62.2)	2.35				34(75.6)	2.02			
19. Creatinine			Λ							
19.1 decreased	4(8.9)	1.75	2/42	1.92	0.15 ^{NS}					
19.2 normal	21(46.7)	2.33	2/72	1.72	0.15	21(46.7)	2.04	43	0.24	0.81^{NS}
19.3 increased	20(44.4)	2.35				24(53.3)	2.00	1.5	0.2 .	0.01
	` ' /					\ - ·- /				
20. ABG analysis										
20.1 yes	18(40.0)	2.38	43	0.92	0.35^{NS}	20(44.4)	2.00	43	0.20	0.82^{NS}
20.2 no	27(60.0)	2.22				25(55.6)	2.04			

t(43) = 2.0167, F (4/40)= 3.126, (3/41)= 3.126, (6/38)=2.3359,(5/39)=2.4495,(2/42)=3.2317

NS-Non significant (p>0.05)

^{*}Significant (p≤0.05)

EXTRA FINDINGS




FIGURE 3. Bar diagram showing level of mean scores of daily assessment of delirium in experimental and comparison group patients admitted in ICU

DISCUSSION

In the present study less than half of the critically ill patients (40%) were in the age group of 62-77 years in experimental group and less than half of the critically ill patients (32.6%) were in age group of 62-77 years in comparison group. These findings are contradictory with the study conducted by **Sharon K. Inouye, Sidney T, Natalia Stanulewicz**, (2020) et al .most of the patients were having age more than 70 years in intervention and usual care group.⁵

In the present study Maximum critically ill patients in experimental group (82.2%) were having no alcohol abuse. The findings were contradictory to a study conducted by **Felipe Martínez**, **MD** (2017) et al the results shows no alcoholism in experimental group (13%).

In the present study there was significant difference in terms of delirium scores after administration of Multicomponent program in experimental and comparison group the mean score of delirium in experimental group was lower than comparison group The findings were supported by a study conducted by **Timothy D Girard1**, (2008) et al the results of the study shows that The intervention significantly reduced delirium (15.0% in the usual care group versus 9.9% in the intervention group; matched OR = 0.60, 95% CI = 0.39 to 0.92).

Another study shows similar findings the study was conducted by **Julie Kalabalik**, (2014) et al the results of study shows Patients in the intervention group experienced shorter duration of delirium (median 2 versus 4 days, P 1/4 .02).⁸

IMPLICATIONS

Nursing Practice:

Nurses should routinely assess the delirium score, of critically ill patients. Nurses should routinely provide Multicomponent program to critically ill patient with MDAS <12...Nurses working in hospital can provide information and administer Multicomponent program and timely helps the critically ill patients to understand about the effect of Multicomponent program and manage the risk of delirium. Nurses should have knowledge about the factors, which enhance and increase the delirium in critically ill patients.

Nursing Research

Further research studies can be in the field of delirium in ICU patients. The findings of the study has generated the evidence about that triggering factors of delirium i.e. sleeping pattern, physical restrain and the effectiveness of Multicomponent program in reducing the level of delirium.

LIMITATIONS

Randomization was not done. Researcher was not blind about patient assignment in experimental and comparison groups; therefore it may introduce biasness in the observation delirium scores. In the present study both the groups were not homogenous because patients of experimental group were sicker. This may have effect on findings of study.

CONCLUSION

The finding of study shows that Multicomponent Program was effective decreasing the level of delirium between experimental and comparison group as there is significant difference between both the groups. Multicomponent Program was effective decreasing the level of delirium within the groups as there is significant difference within the experimental group.

ACKNOWLEDGMENTS

I wish to express my sincere thanks to Dr. (Mrs.) Jyoti Sarin, Director - Principal, for providing moral support and adequate research guidance. I owe my deep gratitude to my advisor Mrs. Pooja Jaswal, Assistant Professor and Dr. B.K. Agrawal, Principal, who took keen interest on my project work. Without their kind direction and proper guidance this project would have been a little success. I am thankful and fortunate enough to get constant encouragement, support and valuable guidance from my family and friends in successfully completing this project This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical Consideration:

Formal administrative approval was obtained from the Hospital to conduct the final study (Ethical no. IEC-1508). The study was carried out in accordance with the guidelines laid by Indian Council of Medical Research. Research participants were enrolled in the study after written informed consent and they were assured about the confidentiality of their response. Purpose of the study was explained to the sample subjects before data collection.

Conflict of Interest: The authors declared no potential conflicts of interest.

Authors Contribution: ¹ M.Sc. Nursing Tutor, Department of Medical Surgical Nursing, M.M. College of Nursing, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, ²RN. RM. MN. Ph.D. (Nursing)Dean- Principal, M.M. College of Nursing, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana. ³RN. RM. M.Sc. (Nursing) Assistant Professor, Department of Community Health Nursing, M.M. College of Nursing, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana. ⁴MD, FICP, FIACM. Principal Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India.

REFRENCES

- 1. Ely EW, Baker AM, Dunagan DP, et al., 1996. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med. 335(25):1864–1869.
- 2. Hodgson C, Bellomo R, Berney S, et al., 2015. Early mobilization and recovery in mechanically ventilated patients in the ICU: a bi-national, multi-centre, prospective cohort study. Crit Care.19:81.
- 3. SchweickertWD, PohlmanMC, PohlmanAS, Nigos C, Pawlik AJ, Esbrook CL, et al., 2009. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet.373(9678):1874–82. https://doi.org/10.1016/S0140-6736(09)60658-9.
- 4. Inouye SK1 et al.,1999. A multicomponent intervention to prevent delirium in hospitalized older patients. N. Engl. J. Med.340:669–676.
- 5.Annmarie Hosie,1 Jane Phillips,1 Lawrence Lam,1 Slavica Kochovska,1 Beverly Noble,1 Meg Brassil,1 Susan E Kurrle,2 Anne Cumming, et al. Multicomponent non-pharmacological intervention to prevent delirium for hospitalised people with advanced cancer: study protocol for a phase II cluster randomised controlled trial BMJ Open: first published as 10.1136/bmjopen-2018-026177 on 28 January 2019.

- 6. Natalia Stanulewicz, Emily Knox, Melanie Narayanasamy, 2020 jan. Effectiveness of Lifestyle Health Promotion Interventions for Nurses: A Systematic Review; Int J Environ Res Public Health. 17(1).
- 7. Felipe Martínez, Ana María Donoso, Carla Marquez et al., 2017 dec. Implementing a Multicomponent Intervention to Prevent Delirium Among Critically III Patients; critical care nursing,37(6):36-46.
- 8. <u>Timothy D Girard, Pratik P Pandharipande</u>, and <u>E Wesley Ely</u> et al., 2008. Delirium in the intensive care unit, <u>Crit Care</u>. 12(Suppl 3).
- 9. Julie Kalabalik, Luigi Brunetti, Luigi Brunetti, et al., 2014. Intensive Care Unit Delirium: A Review of the Literature, journal of pharmacy practice, Vol 27, Issue 2.

